Literature DB >> 12154158

Disease-specific properties of the Rating Scale for Depression in patients with stroke, Alzheimer's dementia, and Parkinson's disease.

Paul Naarding1, Albert F G Leentjens, Fop van Kooten, Frans R J Verhey.   

Abstract

To compare the psychometric properties of the Hamilton Rating Scale for Depression (Ham-D) in patients with stroke, Alzheimer's dementia (AD), and Parkinson's disease (PD), receiver operating characteristic curves were plotted for each group. The concurrent validity of the Ham-D with the DSM-IV criteria for major depressive disorder was high in each of these groups. However, optimal performance of the Ham-D requires the application of disease-specific cutoff scores for screening, diagnostic, and dichotomization purposes. These disease-specific cutoff scores were highest in PD, lower in AD, and lowest in stroke patients.

Entities:  

Mesh:

Year:  2002        PMID: 12154158     DOI: 10.1176/jnp.14.3.329

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  19 in total

1.  Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.

Authors:  Karl Strecker; Florian Wegner; Swen Hesse; Georg-Alexander Becker; Marianne Patt; Philipp M Meyer; Donald Lobsien; Johannes Schwarz; Osama Sabri
Journal:  J Neurol       Date:  2010-07-21       Impact factor: 4.849

2.  Psychometric properties of the Hamilton Depression Rating Scale in multiple sclerosis.

Authors:  Simona Raimo; Luigi Trojano; Daniele Spitaleri; Vittorio Petretta; Dario Grossi; Gabriella Santangelo
Journal:  Qual Life Res       Date:  2015-02-11       Impact factor: 4.147

3.  Depression rating scales in Parkinson's disease: critique and recommendations.

Authors:  Anette Schrag; Paolo Barone; Richard G Brown; Albert F G Leentjens; William M McDonald; Sergio Starkstein; Daniel Weintraub; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

4.  Measuring depression at the end of life: is the Hamilton Depression Rating Scale a valid instrument?

Authors:  Megan Olden; Barry Rosenfeld; Hayley Pessin; William Breitbart
Journal:  Assessment       Date:  2008-08-01

5.  Fatigue in levodopa-naive subjects with Parkinson disease.

Authors:  G Schifitto; J H Friedman; D Oakes; L Shulman; C L Comella; K Marek; S Fahn
Journal:  Neurology       Date:  2008-08-12       Impact factor: 9.910

Review 6.  Detecting depression in Parkinson disease: A systematic review and meta-analysis.

Authors:  Zahra Goodarzi; Kelly J Mrklas; Derek J Roberts; Nathalie Jette; Tamara Pringsheim; Jayna Holroyd-Leduc
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

7.  A comparison of nine scales to detect depression in Parkinson disease: which scale to use?

Authors:  J R Williams; E S Hirsch; K Anderson; A L Bush; S R Goldstein; S Grill; S Lehmann; J T Little; R L Margolis; J Palanci; G Pontone; H Weiss; P Rabins; L Marsh
Journal:  Neurology       Date:  2012-03-14       Impact factor: 9.910

Review 8.  Case identification of depression in patients with chronic physical health problems: a diagnostic accuracy meta-analysis of 113 studies.

Authors:  Nicholas Meader; Alex J Mitchell; Carolyn Chew-Graham; David Goldberg; Maria Rizzo; Victoria Bird; David Kessler; Jon Packham; Mark Haddad; Stephen Pilling
Journal:  Br J Gen Pract       Date:  2011-12       Impact factor: 5.386

9.  Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15).

Authors:  Daniel Weintraub; Sharon Xie; Jason Karlawish; Andrew Siderowf
Journal:  Int J Geriatr Psychiatry       Date:  2007-10       Impact factor: 3.485

10.  Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease.

Authors:  Daniel Weintraub; Katherine A Oehlberg; Ira R Katz; Matthew B Stern
Journal:  Am J Geriatr Psychiatry       Date:  2006-02       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.